¹¹¹In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib

10.1093/jnci/92.3.205

10.1016/j.ejca.2008.10.026

10.1016/j.ctrv.2008.12.001

Takahashi, 1994, Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis, Cancer Res., 54, 4233

Turner, 2002, Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation, Cancer Res., 62, 2957

Raica, 2007, Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma, Neoplasma., 54, 278

10.1038/380439a0

Kusters, 2003, Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma, Cancer Res., 63, 5408

10.1002/ijc.22072

10.1124/pr.56.4.3

10.1091/mbc.4.12.1317

10.2967/jnumed.107.041301

10.1002/ijc.23404

10.1016/j.ejca.2008.05.026

Brouwers, 2004, Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re, J Nucl Med., 45, 327

Collingridge, 2002, The development of [124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography, Cancer Res., 62, 5912

Brouwers, 2003, Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with 131I or 111In: an intrapatient comparison, Clin Cancer Res., 9, 3953S

Scheer MGW Stollman TH Boerman OC . Radiolabeled bevacizumab as a tracer of VEGF-expression in patients with colorectal liver metastasis. Eur J Cancer., in press.

10.1007/s00259-006-0226-z

Span, 2000, EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts, Int J Biol Markers., 15, 184, 10.1177/172460080001500210

10.1126/science.1104819

Oosterwijk-Wakka JC Kats-Ugurlu G Leenders WP . Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2010.

10.1158/0008-5472.CAN-09-3615

Kapoor, 2009, Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma, Curr Oncol., 16, S60

Steffens, 1998, Immunohistochemical analysis of intratumoral heterogeneity of [131I]cG250 antibody uptake in primary renal cell carcinomas, Br J Cancer., 78, 1208, 10.1038/bjc.1998.656

10.1016/S0022-5347(01)65028-6

10.1016/S0959-8049(98)00278-0

10.1111/j.1464-410X.2006.06138.x

10.1002/cncr.23186

10.2214/AJR.09.2941

10.1200/JCO.2007.15.5655